Summary
- Pfizer announced that it had achieved positive top-line results from its phase 3 study using abrocitinb to treat patients with atopic dermatitis (eczema).
- Top-line results showed that those treated with both doses of abrocitinib achieved both co-primary endpoints and all secondary endpoints with statistical significance compared to placebo over a 12-week period.
- Detailed results from the phase 3 study, known as B7451012, will be released at a medical conference and published in a medical journal later this year.
- Another phase 3 study is set to release results from the JADE program, which involves the use of abrocitinib to treat patients with alopecia areata.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today ยป
Pfizer (PFE) announced that it had achieved positive top-line results for its phase 3 study using abrocitinib to treat patients with atopic dermatitis. Specifically, this was for patients who were 12 years of age and older with atopic dermatitis. Not only did the study meet on the co-primary endpoints, but it met on all secondary endpoints as well. The thing is that there is going to be some competition in the space for Pfizer, which it will have to navigate through.
